Scorpius Holdings Inc 's Cash & cash equivalent grew by 15.42 % in the Q3 2025 sequentially, while Current Liabilities decreased, this led to improvement in Scorpius Holdings Inc 's Quick Ratio to 0.03, Quick Ratio remained below Scorpius Holdings inc average.

Within Major Pharmaceutical Preparations industry 511 other companies have achieved higher Quick Ratio than Scorpius Holdings Inc in third quarter 2025. While Quick Ratio total ranking in the third quarter 2025 has deteriorated compared to the prior quarter from 3764 to 4963.

Explain Quick Ratio?
How much Cash & cash equivalents SCPX�s has?
What are SCPX�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

SCPX Quick Ratio	(Sep 30 2025) Q3	(Jun 30 2025) Q2	(Mar 31 2025) Q1	(Dec 31 2024) Q4	(Sep 30 2024) Q3
Y / Y Current Liabilities Change	114.76 %	115.11 %	80.44 %	140.48 %	-57.79 %
Y / Y Cash & cash equivalent Change	-87.51 %	-65.45 %	-85.2 %	-51.36 %	-22.55 %
Quick Ratio MRQ	0.03	0.02	0.01	0.05	0.47
SCPX's Total Ranking	# 4963	# 3764	# 4104	# 3961	# 2203
Seq. Current Liabilities Change	-4.65 %	0.59 %	-4.73 %	135.01 %	-4.49 %
Seq. Cash & cash equivalent Change	15.42 %	108.91 %	-78.58 %	-75.82 %	219.26 %

Quick Ratio third quarter 2025 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 512
Healthcare Sector	# 1009
Overall Market	# 4963

Quick Ratio Statistics
High	Average	Low
43.35	8.44	0.01
(Mar 31 2021)		(Dec 31 2012)

Financial Statements
Scorpius Holdings Inc 's Current Liabilities	$ 22 Millions	Visit SCPX's Balance sheet
Scorpius Holdings Inc 's Cash & cash equivalent	$ 1 Millions	Visit SCPX's Balance sheet
Source of SCPX's Sales		Visit SCPX's Sales by Geography

Cumulative Scorpius Holdings Inc 's Quick Ratio

SCPX's Quick Ratio for the trailling 12 Months

SCPX Quick Ratio	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months	(Mar 31 2025) 12 Months	(Dec 31 2024) 12 Months	(Sep 30 2024) 12 Months
Y / Y Current Liabilities TTM Growth	110.75 %	39.17 %	9.29 %	-13.56 %	-41.73 %
Y / Y Cash & cash equivalent TTM Growth	-75.62 %	-42.82 %	-73.21 %	-83.58 %	-88.76 %
Quick Ratio TTM	0.03	0.08	0.11	0.16	0.24
Total Ranking TTM	# 4254	# 3325	# 3478	# 3566	# 3475
Seq. Current Liabilities TTM Growth	14.64 %	18.16 %	17.7 %	32.19 %	-24.3 %
Seq. Cash & cash equivalent TTM Growth	-62.42 %	-12.76 %	-15.66 %	-11.82 %	-11.88 %

Quick ratio ranking by company, industry and sector >> Back to SCPX Financial Strength Comparisons >> Go to Compare SCPX Quick Ratio to its Competitors

On the trailing twelve months basis Due to decrease in Current Liabilities in the Q3 2025 to $22.20 millions, cumulative Quick Ratio decreased to 0.03 below the Scorpius Holdings Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 503 other companies have achieved higher Quick Ratio than Scorpius Holdings Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2025 from 3325 to 4254.

Explain Quick Ratio?
How much Cash & cash equivalents SCPX�s has?
What are SCPX�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 504
Healthcare Sector	# 1020
Within the Market	# 4254

trailing twelve months Quick Ratio Statistics
High	Average	Low
35.61	7.37	0.03
(Sep 30 2021)		(Sep 30 2025)

Companies with similar Quick Ratio in the quarter ending Sep 30 2025, within Major Pharmaceutical Preparations Industry	Quick Ratio	Sep 30 2025 MRQ Cash & cash equivalent	Sep 30 2025 MRQ Current Liabilities
Polomar Health Services, Inc.	0.07	$ 0.048 Millions	$ 0.672 Millions
Summit Therapeutics Inc	0.07	$ 4.870 Millions	$ 70.933 Millions
Zyversa Therapeutics Inc	0.05	$ 0.697 Millions	$ 12.766 Millions
Northwest Biotherapeutics Inc	0.05	$ 4.560 Millions	$ 87.905 Millions
Blue Water Vaccines Inc	0.05	$ 0.837 Millions	$ 16.303 Millions
Scienture Holdings Inc	0.05	$ 0.356 Millions	$ 7.351 Millions
The Greater Cannabis Company Inc	0.04	$ 0.021 Millions	$ 0.483 Millions
China Pharma Holdings Inc	0.04	$ 0.268 Millions	$ 6.623 Millions
One World Products Inc	0.04	$ 0.169 Millions	$ 4.258 Millions
Abvc Biopharma Inc	0.04	$ 0.257 Millions	$ 6.508 Millions
Lunai Bioworks Inc	0.04	$ 0.625 Millions	$ 16.963 Millions
Scorpius Holdings inc	0.03	$ 0.601 Millions	$ 22.196 Millions
NIKA PHARMACEUTICALS, INC	0.02	$ 0.006 Millions	$ 0.284 Millions
Oncotelic Therapeutics Inc	0.02	$ 0.409 Millions	$ 20.080 Millions
Regen Biopharma Inc	0.01	$ 0.070 Millions	$ 5.549 Millions
Provectus Biopharmaceuticals Inc	0.01	$ 0.072 Millions	$ 6.472 Millions
Aditxt Inc	0.01	$ 0.163 Millions	$ 17.054 Millions
Semnur Pharmaceuticals Inc	0.01	$ 0.085 Millions	$ 10.032 Millions
Prophase Labs Inc	0.01	$ 0.405 Millions	$ 55.287 Millions

Date modified: 2026-09-08T22:08:44+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.